Cadonilimab
Based on 1 publication(s) in Google Scholar
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 2394841-59-7
- Molecular Weight:198.64 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Cadonilimab
More
Biological Activity
IgG1-kappa-[scFv-heavy-lambda]2
Human
CTLA4 & PDCD1
Cadonilimab (0-100 nM, 10-120 min) maintains a high affinity for Jurkat-CTLA4 and Jurkat-PD1 cells in vitro after iodine modification[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Normal KM mice and B-hPD1/hCTLA4-MC38-hPD-L1 mice[4]
-
Dosage:3.7 MBq (Cadonilimab modified with 124I)
-
Administration:tail i.v., a single dose, 2, 24, 96 and 192 h post-injection acquired static PET scans
-
Result:Resulted in higher tumor to nontumor (T/NT) ratios and increaseed the standard uptake value (SUV) value at the tumor site modified with 124I in mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa-[scFv-heavy-lambda]2
ELISA, FACS, Functional assay
-
Immobilized Cadonilimab can bind Human PD-1 Protein (ECD, His Tag). The EC50 for this effect is 0.197 ng/mL. -
Immobilized Cadonilimab can bind Human CTLA-4 Protein (His Tag). The EC50 for this effect is 3.07 ng/mL. -
Immobilized Cadonilimab can bind Human CTLA-4 Protein (His Tag). The EC50 for this effect is 3.07 ng/mL. Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Cadonilimab (anti-CTLA4) (HY-P99117). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Flow Cytometry analysis of THP-1 cells labelling PDCD1 (red) with Cadonilimab (anti-PDCD1) (HY-P99117). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2394841-59-7
-
Appearance Liquid
-
Molecular Weight 198.64 kDa
-
Color Colorless to light yellow
-
SMILES
[Cadonilimab]
-
Synonyms
AK104
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel). 2021 Aug 31;14(9):884. [Content Brief]
[2]. Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296. [Content Brief]
[3]. Chen PY, et al. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab. Front Immunol. 2023 Aug 3;14:1188523. [Content Brief]
[4]. Hou X, et al. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice. Biomed Pharmacother. 2024 Jun;175:116669. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)